Summary
This 8-K filing from Pfizer Inc. on May 16, 2007, serves primarily to furnish financial data in XBRL format as part of the SEC's pilot program. The XBRL-formatted documents are derived from Pfizer's previously filed Q1 2007 10-Q report (filed May 4, 2007) and include condensed consolidated statements of income, balance sheets, and cash flows for relevant periods. Investors are strongly cautioned that this information is unaudited and should not be relied upon for investment decisions. They should continue to refer to the official, audited financial statements as filed with the SEC. The purpose of this filing is purely for testing the XBRL technology and format. As such, the data presented here is not considered 'filed' for liability purposes under the Exchange Act and will not be incorporated into other SEC filings unless expressly stated. This 8-K is a procedural step to support regulatory technology initiatives rather than to report new material events or financial performance.
Key Highlights
- 1Pfizer is participating in the SEC's voluntary XBRL pilot program.
- 2The filing includes XBRL-formatted financial data from Pfizer's Q1 2007 10-Q report.
- 3Data covers condensed consolidated statements of income, balance sheets, and cash flows for specified periods.
- 4Crucially, the XBRL financial data is unaudited and not the official financial statements.
- 5Investors are directed to rely on the official filed versions of Pfizer's financial statements.
- 6Information in this 8-K, including the XBRL exhibits, is not deemed 'filed' for Section 18 liability.
- 7This filing is for technological testing purposes, not for reporting new material events.